 [1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes PHENYTOIN increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does PHENYTOIN increase or decrease the risk of angioedema?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes PHENYTOIN increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes PHENYTOIN increase or decrease the risk of angioedema?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does PHENYTOIN increase the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"phenytoin"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: PHENYTOIN: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Withdrawal Precipitated Seizure : May precipitate status epilepticus. Dose reductions or discontinuation should be done gradually.[0m
[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Serious Dermatologic Reactions : Discontinue phenytoin at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should [0m
[31mnot be resumed and alternative therapy should be considered. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m/[0m[31mMultiorgan[0m[31m hypersensitivity : If signs or symptoms of [0m
[31mhypersensitivity are present, evaluate the patient immediately. Discontinue if an alternative etiology cannot be established. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Hematopoietic Complications: If occurs, follow-up observation is [0m
[31mindicated and an alternative antiepileptic treatment should be used. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5[0m[31m. PHENYTOIN: warnings_and_cautions: [0m[1;31m1[0m[31m Cardiovascular Risk Associated with Rapid Infusion Rapid intravenous administration [0m
[31mof Phenytoin Sodium Injection increases the risk of adverse cardiovascular reactions, including severe hypotension and cardiac arrhythmias. Cardiac arrhythmias have included bradycardia, heart block, [0m
[31mventricular tachycardia, and ventricular fibrillation which have resulted in asystole, cardiac arrest, and death. Severe complications are most commonly encountered in critically ill patients, elderly[0m
[31mpatients, and patients with hypotension and severe myocardial insufficiency. However, cardiac events have also been reported in adults and children without underlying cardiac disease or comorbidities [0m
[31mand at recommended doses and infusion rates. Intravenous administration should not exceed [0m[1;31m50[0m[31m mg per minute in adults. In pediatric patients, administer the drug at a rate not exceeding [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m [0m
[31mmg/kg/min or [0m[1;31m50[0m[31m mg per minute, whichever is slower. PHENYTOIN: warnings_and_cautions: Although the risk of cardiovascular toxicity increases with infusion rates above the recommended infusion rate, [0m
[31mthese events have also been reported at or below the recommended infusion rate. As non-emergency therapy, Phenytoin Sodium Injection should be administered more slowly as either a loading dose or by [0m
[31mintermittent infusion. Because of the risks of cardiac and local toxicity associated with intravenous phenytoin, oral phenytoin should be used whenever possible. Because adverse cardiovascular [0m
[31mreactions have occurred during and after infusions, careful cardiac and respiratory monitoring is needed during and after the administration of intravenous Phenytoin Sodium Injection. Reduction in [0m
[31mrate of administration or discontinuation of dosing may be needed. [0m[1;31m5.2[0m[31m Withdrawal Precipitated Seizure, Status Epilepticus Antiepileptic drugs should not be abruptly discontinued because of the [0m
[31mpossibility of increased seizure frequency, including status epilepticus. PHENYTOIN: warnings_and_cautions: When, in the judgment of the clinician, the need for dosage reduction, discontinuation, or [0m
[31msubstitution of alternative antiepileptic medication arises, this should be done gradually. However, in the event of an allergic or hypersensitivity reaction, rapid substitution of alternative therapy[0m
[31mmay be necessary. In this case, alternative therapy should be an antiepileptic drug not belonging to the hydantoin chemical class. [0m[1;31m5.3[0m[31m Serious Dermatologic Reactions Serious and sometimes fatal [0m
[31mdermatologic reactions, including toxic epidermal necrolysis [0m[1;31m([0m[31mTEN[0m[1;31m)[0m[31m and Stevens-Johnson syndrome [0m[1;31m([0m[31mSJS[0m[1;31m)[0m[31m, have been reported with phenytoin treatment. The onset of symptoms is usually within [0m[1;31m28[0m[31m days, but[0m
[31mcan occur later. Phenytoin should be discontinued at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed[0m
[31mand alternative therapy should be considered. PHENYTOIN: warnings_and_cautions: If a rash occurs, the patient should be evaluated for signs and symptoms of Drug Reaction with Eosinophilia and Systemic[0m
[31mSymptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m [0m[31m . Studies in patients of Chinese ancestry have found a strong association between the risk of developing SJS/TEN and the presence of HLA-B*[0m[1;31m1502[0m[31m, an inherited allelic variant of the [0m
[31mHLA B gene, in patients using carbamazepine. Limited evidence suggests that HLA-B*[0m[1;31m1502[0m[31m may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking other antiepileptic [0m
[31mdrugs associated with SJS/TEN, including phenytoin. PHENYTOIN: warnings_and_cautions: In addition, retrospective, case-control, genome-wide association studies in patients of southeast Asian ancestry [0m
[31mhave also identified an increased risk of SCARs in carriers of the decreased function CYP2C9*[0m[1;31m3[0m[31m variant, which has also been associated with decreased clearance of phenytoin. Consider avoiding [0m
[31mPhenytoin Sodium Injection as an alternative to carbamazepine in patients who are positive for HLA-B*[0m[1;31m1502[0m[31m or in CYP2C9*[0m[1;31m3[0m[31m carriers [0m[31m . The use of HLA-B*[0m[1;31m1502[0m[31m or CYP2C9 genotyping has important [0m
[31mlimitations and must never substitute for appropriate clinical vigilance and patient management. PHENYTOIN: warnings_and_cautions: The role of other possible factors in the development of, and [0m
[31mmorbidity from, SJS/TEN, such as antiepileptic drug [0m[1;31m([0m[31mAED[0m[1;31m)[0m[31m dose, compliance, concomitant medications, comorbidities, and the level of dermatologic monitoring have not been studied. [0m[1;31m5.4[0m[31m Drug Reaction [0m
[31mwith Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m/[0m[31mMultiorgan[0m[31m Hypersensitivity Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m, also known as Multiorgan Hypersensitivity, has been reported [0m
[31min patients taking antiepileptic drugs, including phenytoin. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, [0m
[31mlymphadenopathy, and/or facial swelling, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an[0m
[31macute viral infection. Eosinophilia is often present. PHENYTOIN: warnings_and_cautions: Because this disorder is variable in its expression, other organ systems not noted here may be involved. It is [0m
[31mimportant to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patient [0m
[31mshould be evaluated immediately. Phenytoin Sodium Injection should be discontinued if an alternative etiology for the signs or symptoms cannot be established. [0m[1;31m5.5[0m[31m Hypersensitivity Phenytoin and other [0m
[31mhydantoins are contraindicated in patients who have experienced phenytoin hypersensitivity [0m[31m . Additionally, consider alternatives to structurally similar drugs such as carboxamides [0m[1;31m([0m[31me.g., [0m
[31mcarbamazepine[0m[1;31m)[0m[31m, barbiturates, succinimides, and oxazolidinediones [0m[1;31m([0m[31me.g., trimethadione[0m[1;31m)[0m[31m in these same patients. PHENYTOIN: warnings_and_cautions: Similarly, if there is a history of hypersensitivity [0m
[31mreactions to these structurally similar drugs in the patient or immediate family members, consider alternatives to phenytoin. [0m[1;31m5.6[0m[31m Hepatic Injury Cases of acute hepatotoxicity, including infrequent [0m
[31mcases of acute hepatic failure, have been reported with phenytoin. These events may be part of the spectrum of DRESS or may occur in isolation [0m[31m. Other common manifestations include jaundice, [0m
[31mhepatomegaly, elevated serum transaminase levels, leukocytosis, and eosinophilia. The clinical course of acute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes. In these patients[0m
[31mwith acute hepatotoxicity, phenytoin should be immediately discontinued and not re-administered. [0m[1;31m5[0m[31m. PHENYTOIN: warnings_and_cautions: [0m[1;31m7[0m[31m Hematopoietic Complications Hematopoietic complications, some [0m
[31mfatal, have occasionally been reported in association with administration of phenytoin. These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or [0m
[31mwithout bone marrow suppression. There have been a number of reports suggesting a relationship between phenytoin and the development of lymphadenopathy [0m[1;31m([0m[31mlocal or generalized[0m[1;31m)[0m[31m including benign lymph [0m
[31mnode hyperplasia, pseudolymphoma, lymphoma, and Hodgkin's disease. Although a cause and effect relationship has not been established, the occurrence of lymphadenopathy indicates the need to [0m
[31mdifferentiate such a condition from other types of lymph node pathology. Lymph node involvement may occur with or without symptoms and signs resembling DRESS [0m[31m.         [0m
[31mSOURCE:PHENYTOIN label[0m


[31mCONTENT: PHENYTOIN: pregnancy: [0m[1;31m8.1[0m[31m Pregnancy P regnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs [0m[1;31m([0m[31mAEDs[0m[1;31m)[0m[31m, such [0m
[31mas Phenytoin Sodium Injection, during pregnancy. Physicians are advised to recommend that pregnant patients taking phenytoin enroll in the North American Antiepileptic Drug [0m[1;31m([0m[31mNAAED[0m[1;31m)[0m[31m Pregnancy Registry.[0m
[31mThis can be done by calling the toll free number [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m, and must be done by patients themselves. Information on the registry can also be found at the website [0m
[4;31mhttp://www.aedpregnancyregistry.org/[0m[31m . Risk Summary In humans, prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. Prenatal [0m
[31mphenytoin exposure is associated with an increased incidence of major malformations [0m[1;31m([0m[31mincluding orofacial clefts and cardiac defects[0m[1;31m)[0m[31m. PHENYTOIN: pregnancy: In addition, the fetal hydantoin syndrome a [0m
[31mpattern of abnormalities including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding microcephaly[0m[1;31m)[0m[31m, and cognitive deficits has been reported among [0m
[31mchildren born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy [0m[31m . There have been several reported cases of malignancies, including [0m
[31mneuroblastoma, in children whose mothers received phenytoin during pregnancy. Administration of phenytoin to pregnant animals resulted in an increased incidence of fetal malformations and other [0m
[31mmanifestations of developmental toxicity [0m[1;31m([0m[31mincluding embryofetal death, growth impairment, and behavioral abnormalities[0m[1;31m)[0m[31m in multiple species at clinically relevant doses [0m[31m. In the U.S. general [0m
[31mpopulation, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m to [0m[1;31m20[0m[31m%, respectively. PHENYTOIN: pregnancy: The background [0m
[31mrisk of major birth defects and miscarriage for the indicated population is unknown. Clinical Considerations Disease-associated maternal risk An increase in seizure frequency may occur during [0m
[31mpregnancy because of altered phenytoin pharmacokinetics. Periodic measurement of serum phenytoin concentrations may be valuable in the management of pregnant women as a guide to appropriate adjustment[0m
[31mof dosage [0m[31m . However, postpartum restoration of the original dosage will probably be indicated. Fetal/Neonatal adverse reactions A potentially life-threatening bleeding disorder related to decreased [0m
[31mlevels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero . This drug-induced condition can be prevented with vitamin K administration to the mother before [0m
[31mdelivery and to the neonate after birth. Data Human Data Meta-analyses using data from published observational studies and registries have estimated an approximately [0m[1;31m2[0m[31m.         [0m
[31mSOURCE:PHENYTOIN label[0m


[31mCONTENT: PHENYTOIN: use_in_specific_populations: [0m[1;31m8[0m[31m USE IN SPECIFIC POPULATIONS Pregnancy: Prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse [0m
[31mdevelopmental outcomes. [0m[1;31m([0m[31m [0m[1;31m5.11[0m[31m , [0m[1;31m8.1[0m[31m [0m[1;31m)[0m[31m Renal and/or Hepatic Impairment or Hypoalbuminemia: Monitor unbound phenytoin concentrations in these patients. [0m[1;31m([0m[31m [0m[1;31m8.6[0m[31m [0m[1;31m)[0m[31m [0m[1;31m8.1[0m[31m Pregnancy P regnancy Exposure [0m
[31mRegistry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs [0m[1;31m([0m[31mAEDs[0m[1;31m)[0m[31m, such as Phenytoin Sodium Injection, during pregnancy. Physicians are [0m
[31madvised to recommend that pregnant patients taking phenytoin enroll in the North American Antiepileptic Drug [0m[1;31m([0m[31mNAAED[0m[1;31m)[0m[31m Pregnancy Registry. This can be done by calling the toll free number [0m
[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m, and must be done by patients themselves. PHENYTOIN: use_in_specific_populations: Information on the registry can also be found at the website [0m[4;31mhttp://www.aedpregnancyregistry.org/[0m[31m . [0m
[31mRisk Summary In humans, prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. Prenatal phenytoin exposure is associated with an [0m
[31mincreased incidence of major malformations [0m[1;31m([0m[31mincluding orofacial clefts and cardiac defects[0m[1;31m)[0m[31m. In addition, the fetal hydantoin syndrome a pattern of abnormalities including dysmorphic skull and facial [0m
[31mfeatures, nail and digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding microcephaly[0m[1;31m)[0m[31m, and cognitive deficits has been reported among children born to epileptic women who took phenytoin alone or in [0m
[31mcombination with other antiepileptic drugs during pregnancy [0m[31m . There have been several reported cases of malignancies, including neuroblastoma, in children whose mothers received phenytoin during [0m
[31mpregnancy. PHENYTOIN: use_in_specific_populations: Administration of phenytoin to pregnant animals resulted in an increased incidence of fetal malformations and other manifestations of developmental [0m
[31mtoxicity [0m[1;31m([0m[31mincluding embryofetal death, growth impairment, and behavioral abnormalities[0m[1;31m)[0m[31m in multiple species at clinically relevant doses [0m[31m. In the U.S. general population, the estimated background risk[0m
[31mof major birth defects and of miscarriage in clinically recognized pregnancies is [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m to [0m[1;31m20[0m[31m%, respectively. The background risk of major birth defects and miscarriage for the indicated [0m
[31mpopulation is unknown. Clinical Considerations Disease-associated maternal risk An increase in seizure frequency may occur during pregnancy because of altered phenytoin pharmacokinetics. Periodic [0m
[31mmeasurement of serum phenytoin concentrations may be valuable in the management of pregnant women as a guide to appropriate adjustment of dosage [0m[31m . However, postpartum restoration of the original [0m
[31mdosage will probably be indicated. PHENYTOIN: use_in_specific_populations: Fetal/Neonatal adverse reactions A potentially life-threatening bleeding disorder related to decreased levels of vitamin [0m
[31mK-dependent clotting factors may occur in newborns exposed to phenytoin in utero . This drug-induced condition can be prevented with vitamin K administration to the mother before delivery and to the [0m
[31mneonate after birth. Data Human Data Meta-analyses using data from published observational studies and registries have estimated an approximately [0m[1;31m2.4[0m[31m-fold increased risk for any major malformation in [0m
[31mchildren with prenatal phenytoin exposure compared to controls. An increased risk of heart defects, facial clefts, and digital hypoplasia has been reported. The fetal hydantion syndrome is a pattern [0m
[31mof congenital anomalies including craniofacial anomalies, nail and digital hypoplasia, prenatal-onset growth deficiency, and neurodevelopmental deficiencies.         [0m
[31mSOURCE:PHENYTOIN label[0m


[31mCONTENT: PHENYTOIN: adverse_reactions: The rate of administration is very important; it should not exceed [0m[1;31m50[0m[31m mg per minute in adults, and [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m mg/kg/min [0m[1;31m([0m[31mor [0m[1;31m50[0m[31m mg per minute, whichever is slower[0m[1;31m)[0m[31m in[0m
[31mpediatric patients [0m[31m . Body As a Whole: Allergic reactions in the form of rash and rarely more serious forms [0m[1;31m([0m[31msee Skin and Appendages paragraph below[0m[1;31m)[0m[31m and DRESS [0m[31m have been observed. Anaphylaxis has [0m
[31malso been reported. There have also been reports of coarsening of facial features, systemic lupus erythematosus, periarteritis nodosa, and immunoglobulin abnormalities. Cardiovascular: Severe [0m
[31mcardiovascular events and fatalities have been reported with atrial and ventricular conduction depression and ventricular fibrillation. PHENYTOIN: adverse_reactions: Severe complications are most [0m
[31mcommonly encountered in elderly or critically ill patients [0m[31m . Digestive System: Acute hepatic failure [0m[31m , toxic hepatitis, liver damage, nausea, vomiting, constipation, enlargement of the lips, and [0m
[31mgingival hyperplasia. Hematologic and Lymphatic System: Hematopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin [0m[31m . These have included [0m
[31mthrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. While macrocytosis and megaloblastic anemia have occurred, these conditions [0m
[31musually respond to folic acid therapy. PHENYTOIN: adverse_reactions: Lymphadenopathy, including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin's Disease have been reported [0m[31m. [0m
[31mLaboratory Test Abnormality: Phenytoin may decrease serum concentrations of thyroid hormone [0m[1;31m([0m[31mT4 and T3[0m[1;31m)[0m[31m, sometimes with an accompanying increase in thyroid-stimulating hormone [0m[1;31m([0m[31mTSH[0m[1;31m)[0m[31m, but usually in [0m
[31mthe absence of clinical hypothyroidism. Phenytoin may also produce lower than normal values for dexamethasone or metyrapone tests. Phenytoin may also cause increased serum levels of glucose , alkaline[0m
[31mphosphatase, and gamma glutamyl transpeptidase [0m[1;31m([0m[31mGGT[0m[1;31m)[0m[31m. Nervous System: The most common adverse reactions encountered with phenytoin therapy are nervous system reactions and are usually dose-related. [0m
[31mPHENYTOIN: adverse_reactions: Reactions include nystagmus, ataxia, slurred speech, decreased coordination, somnolence, and mental confusion. Dizziness, vertigo, insomnia, transient nervousness, motor [0m
[31mtwitchings, paresthesia, and headaches have also been observed. There have also been rare reports of phenytoin induced dyskinesias, including chorea, dystonia, tremor and asterixis, similar to those [0m
[31minduced by phenothiazine and other neuroleptic drugs. Cerebellar atrophy has been reported, and appears more likely in settings of elevated phenytoin levels and/or long-term phenytoin use [0m[31m . A [0m
[31mpredominantly sensory peripheral polyneuropathy has been observed in patients receiving long-term phenytoin therapy. Sk in and Appendages: Dermatological manifestations sometimes accompanied by fever [0m
[31mhave included scarlatiniform or morbilliform rashes. PHENYTOIN: adverse_reactions: A morbilliform rash [0m[1;31m([0m[31mmeasles-like[0m[1;31m)[0m[31m is the most common; other types of dermatitis are seen more rarely. Other more [0m
[31mserious forms which may be fatal have included bullous, exfoliative or purpuric dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis [0m[31m . There have also been reports of hypertrichosis. [0m
[31mLocal irritation, inflammation, tenderness, necrosis, and sloughing have been reported with or without extravasation of intravenous phenytoin [0m[31m . Sp ec ial Senses: Altered taste sensation including [0m
[31mmetallic taste. Urogenital: Peyronie’s disease The most common adverse reactions are nervous system reactions, including nystagmus, ataxia, slurred speech, decreased coordination, somnolence, and [0m
[31mmental confusion.         [0m
[31mSOURCE:PHENYTOIN label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Phenytoin does not specifically list angioedema as a risk; however, it does mention the risk of serious dermatologic reactions, including Stevens-Johnson syndrome [0m[1;32m([0m[32mSJS[0m[1;32m)[0m[32m and toxic epidermal [0m
[32mnecrolysis [0m[1;32m([0m[32mTEN[0m[1;32m)[0m[32m, which are severe skin reactions that can be life-threatening. It also notes the occurrence of Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;32m([0m[32mDRESS[0m[1;32m)[0m[32m, also known as Multiorgan [0m
[32mHypersensitivity, which has been reported in patients taking antiepileptic drugs, including phenytoin. These events can be fatal or life-threatening and typically present with fever, rash, and other [0m
[32morgan system involvement. If such signs or symptoms are present, the patient should be evaluated immediately, and phenytoin should be discontinued if an alternative etiology for the signs or symptoms [0m
[32mcannot be established.[0m

[32mSOURCE: PHENYTOIN label[0m
[32mEXTRACT_START_END: Serious Dermatologic Reactions [0m[32m...[0m[32m Multiorgan Hypersensitivity, has been reported [0m[32m...[0m
*[1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Phenytoin does not specifically list angioedema as a risk; however, [0m
[34mit does mention the risk of serious dermatologic reactions, including Stevens-Johnson syndrome [0m[1;34m([0m[34mSJS[0m[1;34m)[0m[34m and toxic epidermal necrolysis [0m[1;34m([0m[34mTEN[0m[1;34m)[0m[34m, which are severe skin reactions that can be life-threatening.[0m
[34mIt also notes the occurrence of Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;34m([0m[34mDRESS[0m[1;34m)[0m[34m, also known as Multiorgan Hypersensitivity, which has been reported in patients taking antiepileptic [0m
[34mdrugs, including phenytoin. These events can be fatal or life-threatening and typically present with fever, rash, and other organ system involvement. If such signs or symptoms are present, the patient[0m
[34mshould be evaluated immediately, and phenytoin should be discontinued if an alternative etiology for the signs or symptoms cannot be established.[0m

[34mSOURCE: PHENYTOIN label[0m
[34mEXTRACT_START_END: Serious Dermatologic Reactions [0m[34m...[0m[34m Multiorgan Hypersensitivity, has been reported [0m[34m...[0m
 [1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does PHENYTOIN increase or decrease the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether PHENYTOIN increases or decreases the risk of angioedema."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that PHENYTOIN does not specifically list angioedema as a risk, but it does mention the risk of serious dermatologic reactions, including Stevens-Johnson syndrome [0m[32m([0m[32mSJS[0m[32m)[0m[32m and[0m
[32mtoxic epidermal necrolysis [0m[32m([0m[32mTEN[0m[32m)[0m[32m, as well as Drug Reaction with Eosinophilia and Systemic Symptoms [0m[32m([0m[32mDRESS[0m[32m)[0m[32m. These conditions can be severe and potentially life-threatening, involving fever, rash, and [0m
[32mother organ system involvement, and require immediate evaluation and potential discontinuation of phenytoin if no other etiology can be established."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"PHENYTOIN does not specifically list angioedema as a risk according to the FDA label. However, it does mention serious dermatologic reactions and hypersensitivity conditions that could [0m
[32mpotentially include symptoms similar to angioedema. Therefore, while angioedema is not explicitly listed, there is a possibility of severe skin and hypersensitivity reactions that could be related to [0m
[32mangioedema-like symptoms."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does PHENYTOIN increase or decrease the risk of angioedema?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether PHENYTOIN increases or decreases the risk of angioedema."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that PHENYTOIN does not specifically list angioedema as a risk, but it does mention the risk of serious dermatologic reactions, including Stevens-Johnson syndrome [0m[34m([0m[34mSJS[0m[34m)[0m[34m and[0m
[34mtoxic epidermal necrolysis [0m[34m([0m[34mTEN[0m[34m)[0m[34m, as well as Drug Reaction with Eosinophilia and Systemic Symptoms [0m[34m([0m[34mDRESS[0m[34m)[0m[34m. These conditions can be severe and potentially life-threatening, involving fever, rash, and [0m
[34mother organ system involvement, and require immediate evaluation and potential discontinuation of phenytoin if no other etiology can be established."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"PHENYTOIN does not specifically list angioedema as a risk according to the FDA label. However, it does mention serious dermatologic reactions and hypersensitivity conditions that could [0m
[34mpotentially include symptoms similar to angioedema. Therefore, while angioedema is not explicitly listed, there is a possibility of severe skin and hypersensitivity reactions that could be related to [0m
[34mangioedema-like symptoms."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does PHENYTOIN increase or decrease the risk of angioedema?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether PHENYTOIN increases or decreases the risk of angioedema.[0m
[1;31m2[0m[31m. FDAHandler responded that PHENYTOIN does not specifically list angioedema as a risk, but it does mention the risk of serious dermatologic reactions, including Stevens-Johnson syndrome [0m[1;31m([0m[31mSJS[0m[1;31m)[0m[31m and [0m
[31mtoxic epidermal necrolysis [0m[1;31m([0m[31mTEN[0m[1;31m)[0m[31m, as well as Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m. These conditions can be severe and potentially life-threatening, involving fever, rash, and [0m
[31mother organ system involvement, and require immediate evaluation and potential discontinuation of phenytoin if no other etiology can be established.[0m
[31m        -----[0m
[31m        Final answer: PHENYTOIN does not specifically list angioedema as a risk according to the FDA label. However, it does mention serious dermatologic reactions and hypersensitivity conditions that[0m
[31mcould potentially include symptoms similar to angioedema. Therefore, while angioedema is not explicitly listed, there is a possibility of severe skin and hypersensitivity reactions that could be [0m
[31mrelated to angioedema-like symptoms.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-PHENYTOIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe question was whether PHENYTOIN increases or decreases the risk of angioedema. According to the FDA label information provided by FDAHandler, PHENYTOIN does not specifically list angioedema as a [0m
[32mrisk. However, the label does mention the risk of serious dermatologic reactions, including Stevens-Johnson syndrome [0m[1;32m([0m[32mSJS[0m[1;32m)[0m[32m and toxic epidermal necrolysis [0m[1;32m([0m[32mTEN[0m[1;32m)[0m[32m, as well as Drug Reaction with [0m
[32mEosinophilia and Systemic Symptoms [0m[1;32m([0m[32mDRESS[0m[1;32m)[0m[32m. These conditions can be severe and potentially life-threatening, involving fever, rash, and other organ system involvement, and require immediate evaluation[0m
[32mand potential discontinuation of phenytoin if no other etiology can be established. Therefore, while angioedema is not explicitly listed, there is a possibility of severe skin and hypersensitivity [0m
[32mreactions that could be related to angioedema-like symptoms.[0m
